PT3325509T - Anticorpos anti-tfr e sua utilização no tratamento de distúrbios proliferativos e inflamatórios - Google Patents

Anticorpos anti-tfr e sua utilização no tratamento de distúrbios proliferativos e inflamatórios

Info

Publication number
PT3325509T
PT3325509T PT167443530T PT16744353T PT3325509T PT 3325509 T PT3325509 T PT 3325509T PT 167443530 T PT167443530 T PT 167443530T PT 16744353 T PT16744353 T PT 16744353T PT 3325509 T PT3325509 T PT 3325509T
Authority
PT
Portugal
Prior art keywords
inflammatory disorders
treating proliferative
tfr antibodies
tfr
antibodies
Prior art date
Application number
PT167443530T
Other languages
English (en)
Original Assignee
Inatherys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inatherys filed Critical Inatherys
Publication of PT3325509T publication Critical patent/PT3325509T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT167443530T 2015-07-22 2016-07-21 Anticorpos anti-tfr e sua utilização no tratamento de distúrbios proliferativos e inflamatórios PT3325509T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15306192 2015-07-22

Publications (1)

Publication Number Publication Date
PT3325509T true PT3325509T (pt) 2021-03-12

Family

ID=53776520

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167443530T PT3325509T (pt) 2015-07-22 2016-07-21 Anticorpos anti-tfr e sua utilização no tratamento de distúrbios proliferativos e inflamatórios

Country Status (23)

Country Link
US (2) US11230605B2 (pt)
EP (1) EP3325509B1 (pt)
JP (1) JP6858185B2 (pt)
KR (1) KR20180028519A (pt)
CN (1) CN107849136B (pt)
AU (1) AU2016296321B2 (pt)
BR (1) BR112018000650A2 (pt)
CA (1) CA2992509A1 (pt)
CY (1) CY1123941T1 (pt)
DK (1) DK3325509T3 (pt)
ES (1) ES2860988T3 (pt)
HK (1) HK1256088A1 (pt)
HR (1) HRP20210393T1 (pt)
HU (1) HUE053296T2 (pt)
IL (1) IL257065B (pt)
LT (1) LT3325509T (pt)
MX (1) MX2018000569A (pt)
PL (1) PL3325509T3 (pt)
PT (1) PT3325509T (pt)
RS (1) RS61586B1 (pt)
RU (1) RU2737637C2 (pt)
SI (1) SI3325509T1 (pt)
WO (1) WO2017013230A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4029880A1 (en) 2015-05-04 2022-07-20 CytomX Therapeutics, Inc. Activatable anti-cd71 antibodies, and methods of use thereof
FR3062213B1 (fr) 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
SG11202100934PA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3108289A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US20220411527A1 (en) * 2019-11-06 2022-12-29 The Regents Of The University Of California Compositions and methods for transferrin receptor 1 targeting
AU2021213042A1 (en) * 2020-01-31 2022-09-22 Dyne Therapeutics, Inc. Anti-transferrin receptor (TfR) antibody and uses thereof
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11827702B2 (en) 2021-09-01 2023-11-28 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
WO2023039611A2 (en) * 2021-09-13 2023-03-16 The Board Of Regents Of The University Of Texas System Tfr antigen binding proteins and uses thereof
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
ES2694002T3 (es) * 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
PT1545613E (pt) 2002-07-31 2011-09-27 Seattle Genetics Inc Conjugados de auristatina e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infecciosa
WO2005011082A2 (en) 2003-07-23 2005-02-03 Univeral Infusion Technology Drive motor transmission system
ATE537189T1 (de) * 2004-04-30 2011-12-15 Inst Nat Sante Rech Med Anti-tfr-antikörper
JP4824025B2 (ja) * 2004-06-07 2011-11-24 マクロジェニックス ウエスト,インコーポレイテッド トランスフェリンレセプター抗体
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
FR2953841B1 (fr) * 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
JP2015524816A (ja) * 2012-08-02 2015-08-27 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用
HUE039920T2 (hu) * 2012-11-08 2019-02-28 Univ Miyazaki Transzferrin receptor specifikusan felismerni képes antitest
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer

Also Published As

Publication number Publication date
JP2018521691A (ja) 2018-08-09
HK1256088A1 (zh) 2019-09-13
EP3325509B1 (en) 2020-12-16
ES2860988T3 (es) 2021-10-05
IL257065A (en) 2018-03-29
AU2016296321A1 (en) 2018-01-25
RS61586B1 (sr) 2021-04-29
DK3325509T3 (da) 2021-03-08
PL3325509T3 (pl) 2021-07-19
SI3325509T1 (sl) 2021-07-30
IL257065B (en) 2022-07-01
US11230605B2 (en) 2022-01-25
JP6858185B2 (ja) 2021-04-14
KR20180028519A (ko) 2018-03-16
WO2017013230A1 (en) 2017-01-26
BR112018000650A2 (pt) 2018-09-18
EP3325509A1 (en) 2018-05-30
CN107849136B (zh) 2022-04-01
RU2018106364A (ru) 2019-08-22
HUE053296T2 (hu) 2021-06-28
LT3325509T (lt) 2021-06-10
CA2992509A1 (en) 2017-01-26
MX2018000569A (es) 2018-09-27
RU2018106364A3 (pt) 2019-08-22
AU2016296321B2 (en) 2022-09-08
RU2737637C2 (ru) 2020-12-01
CN107849136A (zh) 2018-03-27
CY1123941T1 (el) 2022-05-27
US20220119543A1 (en) 2022-04-21
US20190092870A1 (en) 2019-03-28
HRP20210393T1 (hr) 2021-04-30

Similar Documents

Publication Publication Date Title
HK1256088A1 (zh) 抗tfr抗體及其在治療增殖性和炎性疾病中的用途
HK1243005A1 (zh) 抗lilrb抗體及其在檢測和治療癌症中的用途
IL256687B (en) Isolated tau-binding antibody and its use in treatment and diagnosis
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
IL240135A0 (en) Anti-il-17 antibodies and their use in the treatment of autoimmune and inflammatory disorders
GB201511382D0 (en) Novel compounds and their use in therapy
IL252118A0 (en) Analytical methods and arrays for their use
GB201507722D0 (en) Anti-bacterial agents and their use in therapy
GB201410226D0 (en) Methods and arrays for use in the same
GB201507723D0 (en) Anti-bacterial agents and their use in therapy
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
GB201507721D0 (en) Immunosuppressive agents and their use in therapy
GB201614318D0 (en) Methods and compositions used in treating inflammatory and autoimmune diseases
HK1217913A1 (zh) 阿地米屈在治療上皮功能障礙中的用途
FI20155623A (fi) Järjestely ja menetelmä kuorman säätämiseksi harjoitteluvälineessä
GB2522647B (en) Hair smoothing and conditioning apparatus
PL3262069T3 (pl) Zastosowanie przeciwciał i antagonistów skierowanych przeciwko LRG1 w leczeniu
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201409978D0 (en) Novel compounds and their use in therapy
GB201503053D0 (en) Apparatus for use in magnetic hyperthermia treatments